Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and cannot pump blood well)
- People who have a specific antibody in their blood called an anti-β1-adrenergic receptor antibody (confirm with trial site)
- People between 18 and 75 years old
- People whose heart pumping function, measured by an ultrasound of the heart, shows the heart is pumping at 40% or less of its normal capacity
- People whose heart failure symptoms fall into a moderate-to-severe range on a standard medical scale (NYHA class II to IV)
- People who have had heart failure symptoms for at least 6 months
- People who have been on a stable, guideline-recommended combination of heart failure medications for at least 6 months, with no dose changes in the past month (not counting water pills/diuretics)
- People whose condition is currently stable and not in an emergency state
- People who have given their written agreement to take part in the trial
Who may not be able to join:
- People who received a defibrillator device (ICD) less than 1 month ago, or a cardiac resynchronisation device (CRT/D) less than 6 months ago
- People whose heart failure is caused by a different underlying heart condition
- People with very advanced heart failure who cannot stop receiving heart-support drugs given through a drip (IV)
- People whose life expectancy is less than 1 year
- People with a low red blood cell level (anaemia below a certain threshold)
- People who require medications that suppress the immune system
- People who have another serious or active illness at the same time, such as a serious infection, severe liver or kidney problems, blood disorders, cancer, severe malnutrition, or autoimmune diseases
- People who have previously been treated with immunoadsorption therapy or intravenous immunoglobulin therapy
- People who have conditions that make certain medical procedures involving blood circulation outside the body unsafe, such as serious mental illness, loss of consciousness, shock, severe bleeding or clotting problems, or multiple organ failure
- People who are pregnant or breastfeeding
- People who have any other condition that the trial doctors believe could increase their risk or affect the trial results, such as severe anxiety, alcohol or drug misuse, or significant cognitive impairment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiang Cheng, M.D., Ph.D., Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: +86-18107265338
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in LVEF from baseline to 6 months determined by echocardiography
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.